91475-00-2

Upstream product

• 135103-27-4 C₁₆H₂₃NO₅*C₁₂H₂₃N 
• 73584-84-6 (S)-2-(tert-butoxycarbonyl(methyl)amino)-3-(4-methoxyphenyl)propanoic acid 
• 115441-65-1 methyl N-Cbz-N,O-dimethyl-L-tyrosyl-L-alaninate 
• 115441-64-0 methyl N-Cbz-N-methyl-L-tyrosyl-L-alaninate 
• 86099-14-1 (2S)-3-(4-hydroxyphenyl)-2-(methyl{[(phenylmethyl)oxy]carbonyl}amino)propanoic acid 
• 15761-38-3 L-N-Boc-Ala 
• 91474-98-5 methyl O,N-dimethyl-L-tyr-L-alaninate 
• 91474-97-4 methyl O,N-dimethyl-N-boc-L-tyr-L-alaninate 

Downstream Products

• 694491-76-4 (S)-2-[(S)-2-{[(S)-2-((R)-2-Benzyloxycarbonylamino-butyrylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionic acid methyl ester 
• 1372157-31-7 [Tyr-5-ψ(CH2NMe)-Tyr-6]RA-VII 
• 112196-84-6 BOC-D-Ala-L-Ala-NMe-L-Tyr(OMe)-L-Ala-OH 
• 138571-40-1 C₄₅H₅₈N₆O₁₂ 
• 91475-02-4 methyl N-boc-N-methyl-L-tyr-N-methyl-L-tyr-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91502-35-1 methyl N-methyl-L-tyr-N-methyl-L-tyr-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91474-95-2 methyl D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91502-34-0 cyclo-N-methyl-L-tyr-N-methyl-L-tyr-D-ala-L-ala-O,N-dimethyl-L-tyr-L-ala 
• 91475-01-3 methyl N-boc-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 675129-54-1 C₅₂H₆₄N₆O₁₂ 
• 675129-57-4 C₄₇H₅₆N₆O₁₀ 
• 122546-77-4 12-({2-[2-{[2-(2-amino-acetylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-4-methoxy-10-methyl-11-oxo-2-oxa-10-aza-tricyclo[12.2.2.1^3,7]nonadeca-1⁽¹⁷⁾,3⁽¹⁹⁾,4,6,14⁽¹⁸⁾,15-hexaene-9-carboxylic acid 
• 675129-45-0 Boc-Gly-Ala-N,O-dimethyl-Tyr-Ala-OH 
• 675129-44-9 Boc-Gly-Ala-N,O-dimethyl-Tyr-Ala-OMe 

Relevant academic research and scientific papers

BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF

The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvar

Synthesis of [Gly-1]RA-VII, [Gly-2]RA-VII, and [Gly-4]RA-VII. Glycine-Containing Analogues of RA-VII, an Antitumor Bicyclic Hexapeptide from Rubia Plants

Three analogues of RA-VII (1), an antitumor bicyclic hexapeptide from Rubia plants, were synthesized. Three analogues, [Gly-1]RA-VII (4), [Gly-2]RA-VII (5), and [Gly-4]RA-VII (6), in which one of the three alanine residues in 1 was replaced by a glycine r

Isolation, structural elucidation, and synthesis of RA-XVII, a novel bicyclic hexapeptide from Rubia cordifolia, and the effect of side chain at residue 1 upon the conformation and cytotoxic activity

A novel antitumor bicyclic hexapeptide RA-XVII was isolated from the roots of Rubia cordifolia. By spectral studies and synthetic approach, its structure was determined to be [D-2-aminobutyric acid-1]deoxybouvardin. Studies on the effect of side chain at

SYNTHESIS OF CYCLO-N-METHYL-L-TYR-N-METHYL-L-TYR-D-ALA-L-ALA-O,N-DIMETHYL-L-TYR-L-ALA, A CYCLIC HEXAPEPTIDE RELATED TO THE ANTITUMOR AGENT DEOXYBOUVARDIN

A synthesis of the title cyclic hexapeptide is described.Its lack of antitumor activity shows that the 14-membered ring of deoxybouvardin is needed for activity.Efforts to oxidatively its phenolic groups failed to give deoxybouvardin.